Tonix Pharmaceuticals to present PTSD program at the MicroCap Conference in New York

|About: Tonix Pharmaceuticals Hold... (TNXP)|By:, SA News Editor

Tonix Pharmaceuticals (NASDAQ:TNXP) will present at the MicroCap Conference being held April 9-10, in New York City.

Tonix is in Phase 3 development of Tonmya, or TNX-102 SL, a FDA-designated Breakthrough Therapy for the treatment of posttraumatic stress disorder (PTSD).

Previously: Tonix Pharmaceuticals achieves 50% enrollment in Phase 3 trial of Tonmya for the treatment of PTSD (April 3)

Subscribe for full text news in your inbox